RepliCel Life Sciences Inc (REPCF)
OTHER OTC:REPCF
Want to see REPCF full AI Analyst Report?
Total Valuation
RepliCel Life Sciences has a market cap or net worth of $770.08K. The enterprise value is ―.
Market Cap$770.08K
Enterprise Value―
Share Statistics
RepliCel Life Sciences has 73,577,805 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding73,577,805
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
RepliCel Life Sciences’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is -29.95%.
Return on Equity (ROE)0.08
Return on Assets (ROA)-4.14
Return on Invested Capital (ROIC)-29.95%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover3.64
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of RepliCel Life Sciences is ―. RepliCel Life Sciences’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value>-0.01
Price to FCF0.00
Price to Operating Cash Flow-0.66
PEG Ratio―
Income Statement
In the last 12 months, RepliCel Life Sciences had revenue of 353.44K and earned -401.63K in profits. Earnings per share was >-0.01.
Revenue353.44K
Gross Profit0.00
Operating Income237.84K
Pretax Income-247.03K
Net Income-401.63K
EBITDA237.84K
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -296.08K and capital expenditures 4.00, giving a free cash flow of -296.08K billion.
Operating Cash Flow-296.08K
Free Cash Flow-296.08K
Free Cash Flow per Share>-0.01
Dividends & Yields
RepliCel Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta177.96
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)100.00
Average Volume (3m)2.62K
Important Dates
RepliCel Life Sciences upcoming earnings date is Jun 2, 2026, TBA (Confirmed).
Last Earnings DateAug 27, 2025
Next Earnings DateJun 2, 2026
Ex-Dividend Date―
Financial Position
RepliCel Life Sciences as a current ratio of 0.02, with Debt / Equity ratio of -19.27%
Current Ratio0.02
Quick Ratio0.02
Debt to Market Cap106.37
Net Debt to EBITDA4.27
Interest Coverage Ratio5.82
Taxes
In the past 12 months, RepliCel Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
RepliCel Life Sciences EV to EBITDA ratio is 4.31, with an EV/FCF ratio of -3.46.
EV to Sales2.90
EV to EBITDA4.31
EV to Free Cash Flow-3.46
EV to Operating Cash Flow-3.46
Balance Sheet
RepliCel Life Sciences has $5.52K in cash and marketable securities with $1.24M in debt, giving a net cash position of -$1.02M billion.
Cash & Marketable Securities$5.52K
Total Debt$1.24M
Net Cash-$1.02M
Net Cash Per Share-$0.01
Tangible Book Value Per Share-$0.07
Margins
Gross margin is 100.00%, with operating margin of 67.29%, and net profit margin of -113.63%.
Gross Margin100.00%
Operating Margin67.29%
Pretax Margin-69.89%
Net Profit Margin-113.63%
EBITDA Margin67.29%
EBIT Margin67.29%
Analyst Forecast
The average price target for RepliCel Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-75.68%
EPS Growth Forecast-567.07%